Key Highlights

  • Context Therapeutics (NASDAQ:CNTX) reported a second quarter 2026 net loss of USD 14.56 million, up 65% from USD 8.83 million, or USD 0.15 per share, with cash of USD 43 million at June 30, 2026.
  • Management said cash funds operations through the fourth quarter of 2027. Its lead candidate CTIM-76 received FDA Fast Track Designation in April 2026, and a Phase 1b expansion is expected to start in the first quarter of 2027.
  • Published coverage reported a close of USD 0.69 on August 5, 2026, then a fall of 23.06% to USD 0.53 in overnight trading, single source figures we treat as approximate.
  • Published market data show CNTX at USD 0.20, up 6.82% in the latest session on 1.29 million shares, with a Market Value of USD 18.56 million. These screener figures are unverified.

A Loss That Widened With the Pipeline

Context Therapeutics reported second quarter results in early August 2026. The net loss widened 65% to USD 14.56 million as spending on its programmes rose, and cash was USD 43 million at June 30. The company said that funds operations through the fourth quarter of 2027. CTIM-76, a bispecific antibody for platinum resistant ovarian cancer, received FDA Fast Track designation in April 2026. A second candidate, CT-202, received Australian clearance to begin a first in human trial, with initial data expected in the second half of 2027. Context Therapeutics (NASDAQ:CNTX) discontinued CT-95 to focus resources.

From USD 0.69 to USD 0.20

Penny stock screens list low priced shares, and Context now qualifies. Published coverage reported a close of USD 0.69 on August 5, 2026, up 11.45%, then an overnight fall of 23.06% to USD 0.53 after the results. The screener price of USD 0.20 would be about 71% below USD 0.69, our own arithmetic on one single source number and one unverified screener number. We found no filing explaining the fall since August. Screener data show a market value of USD 18.56 million, well below the USD 43 million of cash reported at June 30, though cash has been spent since and the comparison is only indicative. The company also amended its BioAtla licence in May 2026, removing future milestone and Royalty obligations.

Risks and What to Watch

A small number of trades can move a stock this size, spreads can be wide and a quoted gain such as 6.82% can reverse quickly, so it should not be read as a recovery. Clinical stage cancer drugs Fail often, and Phase 1 data in a few patients rarely predict approval. A financing before the end of 2027 is likely, which would dilute holders. Trading below USD 1.00 can lead to a Nasdaq compliance notice, though we have not seen one. Investors should watch the first patient dosing in the CT-202 trial, the start of the CTIM-76 expansion in the first quarter of 2027 and any Capital raise. Management also guided that early data from CT-202 are not due until the second half of 2027, so there may be few clinical catalysts in the near term.

Where Things Stand

Context could recover if early cancer data are strong or if investors decide the market value of USD 18.56 million undervalues its USD 43 million of June cash, but nothing in the filings guarantees it. The share price has fallen about 71% from the August close on mixed sources. Context Therapeutics (NASDAQ:CNTX) has a runway into late 2027 and two clinical programmes, yet dilution, trial risk and thin trading keep it a speculative name.